---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-046908"
form_type: "8-K"
ticker: "BTCY"
cik: "0001630113"
company_name: "BIOTRICITY INC."
filed_at: "2024-11-20T23:59:59+00:00"
generated_at: "2026-05-29T21:50:55.677249+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biotricity Q2 FY2025 revenue up 13% YoY to $3.3M; net loss down 57% to $1.65M

## Summary
- Revenue $3.3M (+13% YoY); gross margin improved to 75.3% from 69.1%.
- Net loss decreased 57% to $1.65M ($0.073/share) from $3.88M in Q2 FY24.
- Recurring tech fees $3.06M (+12.2%), 94% of total revenue; flat fee portion up 34%.
- Achieved positive cash flow on current operating basis in September; expects continued improvement.
- SG&A cut 35.5% to $2.25M; total operating expenses down 34% YoY.

## SEC filing metadata
- accession: 0001493152-24-046908
- form_type: 8-K
- ticker: BTCY
- cik: 0001630113
- company_name: BIOTRICITY INC.
- filed_at: 2024-11-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630113/000149315224046908/0001493152-24-046908-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630113/000149315224046908/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-046908
- JSON: https://secwatch.observer/filing/0001493152-24-046908.json
- Plain text: https://secwatch.observer/filing/0001493152-24-046908.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.